Blood Pressure Alterations in CML Patients Treated with Imatinib vs. Nilotinib: A Clinical Insight

Chronic Myeloid Leukemia is a hematologic malignancy characterized by the BCR-ABL fusion gene. Tyrosine Kinase Inhibitors such as imatinib and nilotinib have significantly improved the prognosis for CML patients. However, prolonged TKI therapy is associated with cardiovascular side effects, particul...

Descripció completa

Dades bibliogràfiques

Autors principals:	Anwar Wardiyanti, Harjianti Tutik, Tandean Pendrik, Bakri Syakib, Hp Faridin, Zainuddin Andi Alfian
Format:	Artigo
Idioma:	Inglês
Publicat:	Sciendo 2026-04-01
Col·lecció:	Romanian Journal of Internal Medicine
Matèries:	chronic myeloid leukemia (cml) tyrosine kinase inhibitors (tkis) blood pressure changes imatinib nilotinib
Accés en línia:	https://doi.org/10.2478/rjim-2026-0005
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!